KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash & Equivalents (2016 - 2025)

NovoCure's Cash & Equivalents history spans 12 years, with the latest figure at $93.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 42.88% year-over-year to $93.5 million; the TTM value through Dec 2025 reached $93.5 million, down 42.88%, while the annual FY2025 figure was $93.5 million, 42.88% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $93.5 million at NovoCure, down from $342.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $689.8 million in Q3 2021 and bottomed at $93.5 million in Q4 2025.
  • The 5-year median for Cash & Equivalents is $188.4 million (2022), against an average of $244.9 million.
  • The largest annual shift saw Cash & Equivalents soared 194.22% in 2021 before it crashed 71.95% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $208.8 million in 2021, then plummeted by 44.77% to $115.3 million in 2022, then skyrocketed by 108.82% to $240.8 million in 2023, then crashed by 32.0% to $163.8 million in 2024, then crashed by 42.88% to $93.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Cash & Equivalents are $93.5 million (Q4 2025), $342.1 million (Q3 2025), and $149.6 million (Q2 2025).